Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC-Reference-Cited by-同舟云学术

Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC

Published:2023-04 Issue:4 Volume:4 Page:100474
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Jo Hitomi,Yoshida Tatsuya,Yagishita Shigehiro,Ohuchi Mayu,Matsumoto Yuji,Shinno Yuki,Okuma Yusuke,Goto Yasushi,Horinouchi Hidehito,Yamamoto Noboru,Takahashi Kazuhisa,Motoi Noriko,Hamada Akinobu,Ohe Yuichiro

Funder

National Cancer Center

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference28 articles.

1. Five-year outcomes from the randomized, Phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer;Borghaei;J Clin Oncol,2021

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC;Herbst;J Thorac Oncol,2021

4. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater;Reck;J Clin Oncol,2019

5. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial;Rittmeyer;Lancet,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort;Investigational New Drugs;2024-08-21

2. Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer;Clinical Cancer Research;2023-07-11